Search

Your search keyword '"Huis‐Tanja, Lieke H."' showing total 18 results
Start Over Author "Huis‐Tanja, Lieke H."
18 results on '"Huis‐Tanja, Lieke H."'

2. Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)

Author

Beerepoot, Laurens V., Creemers, Geert-Jan, van Cruijsen, Hester, de Groot, Jan Willem B., van Halteren, Henk K., Helgason, Helgi H., Hendriks, Mathijs P., Hoekstra, Ronald, van Huis-Tanja, Lieke H., Kapiteijn, Ellen, Los, Maartje, van Meerten, Esther, Peters, Natascha A.J.B., Pruijt, Johannes F.M., van Ufford-Mannesse, Patricia Quarles, Sie, Mark P.S., Sommeijer, Dirkje W., Spierings, Leontine E.A.M.M., Terheggen, Frederiek, Tjin-A-Ton, Manuel L.R., Valkenburg-van Iersel, Liselot B.J., van Voorthuizen, Theo, de Vos-Geelen, Judith, Vulink, Annelie J.E., J van de Wouw, Agnès, Hamers, Patricia A.H., Vink, Geraldine R., Elferink, Marloes A.G., Stellato, Rebecca K., Dijksterhuis, Willemieke P.M., Punt, Cornelis J.A., Koopman, Miriam, and May, Anne M.

Published
2022
Full Text
View/download PDF

7. Quality of Life and Survival of Metastatic Colorectal Cancer Patients Treated With Trifluridine-Tipiracil (QUALITAS)

Author

Hamers, Patricia A.H., primary, Vink, Geraldine R., additional, Elferink, Marloes A.G., additional, Stellato, Rebecca K., additional, Dijksterhuis, Willemieke P.M., additional, Punt, Cornelis J.A., additional, Koopman, Miriam, additional, May, Anne M., additional, Beerepoot, Laurens V., additional, Creemers, Geert-Jan, additional, van Cruijsen, Hester, additional, de Groot, Jan Willem B., additional, van Halteren, Henk K., additional, Helgason, Helgi H., additional, Hendriks, Mathijs P., additional, Hoekstra, Ronald, additional, van Huis-Tanja, Lieke H., additional, Kapiteijn, Ellen, additional, Los, Maartje, additional, van Meerten, Esther, additional, Peters, Natascha A.J.B., additional, Pruijt, Johannes F.M., additional, van Ufford-Mannesse, Patricia Quarles, additional, Sie, Mark P.S., additional, Sommeijer, Dirkje W., additional, Spierings, Leontine E.A.M.M., additional, Terheggen, Frederiek, additional, Tjin-A-Ton, Manuel L.R., additional, Valkenburg-van Iersel, Liselot B.J., additional, van Voorthuizen, Theo, additional, de Vos-Geelen, Judith, additional, Vulink, Annelie J.E., additional, and J van de Wouw, Agnès, additional

Published
2022
Full Text
View/download PDF

12. The G8 frailty screening tool and the decision‐making process in older breast cancer patients.

Author

Scheepers, Ellen R. M., Molen, Loes F., Bos, Frederiek, Burgmans, Josephine P., Huis‐Tanja, Lieke H., and Hamaker, Marije E.

Subjects
BREAST cancer prognosis, BREAST tumor treatment, GERIATRIC assessment, BREAST tumors, CHI-squared test, STATISTICAL correlation, FRAIL elderly, MULTIVARIATE analysis, REGRESSION analysis, SURVIVAL analysis (Biometry), DECISION making in clinical medicine, PROPORTIONAL hazards models, RETROSPECTIVE studies, DATA analysis software, DESCRIPTIVE statistics, KAPLAN-Meier estimator, OLD age
Abstract

Objective: To assess the decision‐making process in fit and frail older breast cancer patients. Methods: Breast cancer patients aged ≥70 years who completed the G8 frailty screening tool (G8) were included in this retrospective study. Socio‐demographic and clinical characteristics were collected, as well as information from geriatric assessment (GA). Treatment decisions were compared with national guidelines. Results: Of 177 patients, 85 patients were considered fit by the G8 (G8‐fit) and 92 patients frail (G8‐frail). All G8‐fit and 53 G8‐frail were proposed for surgery. GA was performed in 34 patients (9 G8‐fit; 25 G8‐frail) of whom 16 (2 G8‐fit;14 G8‐frail) were considered frail (GA‐frail). 28 out of these 34 patients were considered fit for surgery (including 11 GA‐frail); their impairments were unlikely to interfere with surgery or life expectancy. Reasons for adjusting treatment were physical/cognitive condition and patient preference. Ultimately, 123 patients underwent surgery in accordance with guidelines (81 G8‐fit;42 G8‐frail, p < 0.001). Survival was reduced in G8‐frail compared to G8‐fit (p = 0.001), but G8 lost its association with mortality in multivariable survival analysis. Among patients undergoing surgery, no difference in mortality was seen between G8‐fit and G8‐frail (p = 0.996). Conclusion: The G8 is associated with treatment decisions and did not affect survival in patients undergoing surgery. In the decision‐making process, the G8 may help and estimates the need for adaptive care. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

13. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing

Author

van Kuilenburg, André B.P., primary, Meijer, Judith, additional, Maurer, Dirk, additional, Dobritzsch, Doreen, additional, Meinsma, Rutger, additional, Los, Maartje, additional, Knegt, Lia C., additional, Zoetekouw, Lida, additional, Jansen, Rob L.H., additional, Dezentjé, Vincent, additional, van Huis-Tanja, Lieke H., additional, van Kampen, Roel J.W., additional, Hertz, Jens Michael, additional, and Hennekam, Raoul C.M., additional

Published
2017
Full Text
View/download PDF

17. MTHFRpolymorphisms and capecitabine-induced toxicity in patients with metastatic colorectal cancer

Author

Huis-Tanja, Lieke H. van, Gelderblom, Hans, Punt, Cornelis J.A., and Guchelaar, Henk-Jan

Abstract

The availability of current chemotherapeutic options for metastatic colorectal cancer (mCRC) has increased survival, but it is also accompanied by considerable morbidity. Fluoropyrimidines are the mainstay of systemic therapy. Germline pharmacogenetic markers involved in 5-fluorouracil pharmacodynamics could provide individualized pretreatment tools for predicting toxicity. Research on methylenetetrahydrofolate reductase (MTHFR)gene polymorphisms and fluoropyrimidine treatment outcome has focused on intravenous 5-fluorouracil and has yielded inconclusive results. The literature on pharmacogenetics in capecitabine-based chemotherapy is scarce. Therefore, we analysed the association of MTHFRgene polymorphisms and the occurrence of serious toxicity of first-line capecitabine monotherapy and combination therapy.

Published
2013
Full Text
View/download PDF

18. [Patient or disease in oncology?]

Author

Hamaker ME, Seghers PALN, and van Huis-Tanja LH

Subjects
Humans, Medical Oncology, Patient-Centered Care, Quality of Life
Abstract

Patients need to be well informed about those outcomes that matter most to them to be able to make good decisions between different oncologic treatment options. Research shows that patient-centred data on quality of life and physical, social and cognitive functions are important to patients besides the more commonly used disease-centred outcomes. Current design and reporting of outcomes in oncologic studies does not provide enough information on these necessary patient-centred outcomes. Optimizing oncologic care and research requires a patient-centred focus instead of a disease-centred focus.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results